2026 ICD-10-CM Diagnosis Code E88.3Tumor lysis syndrome
ICD-10-CM Codes›E00–E89›E70-E88›E88
- Billable — Valid for Submission
- MCC — Major Complication or Comorbidity
- Chronic Condition
E88.3 is a billable ICD-10-CM diagnosis code for tumor lysis syndrome. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 673 through 675, 682 through 684, 791, 793. As a secondary diagnosis, it counts as a major complication or comorbidity (MCC) and places an inpatient stay in the highest severity level of its MS-DRG family. It does not count, however, when the principal diagnosis is one of 78 closely related codes. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Conditions due to neoplasm or the treatment of neoplasm and Other specified and unspecified nutritional and metabolic disorders.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Tumor lysis syndrome
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Tumor lysis syndrome (spontaneous)
- Tumor lysis syndrome following antineoplastic drug chemotherapy
Use Additional Code
- code for adverse effect, if applicable, to identify drug T45.1X5
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
The “use additional code” indicates that a secondary code could be used to further specify the patient’s condition. This note is not mandatory and is only used if enough information is available to assign an additional code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Syndrome See Also: Disease;
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Tumor Lysis Syndrome
a syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. it is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
Patient EducationClinical
Lymphoma
Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E88.3 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About E88.3Overview
What is the ICD-10 code for tumor lysis syndrome?
The ICD-10-CM code for tumor lysis syndrome is E88.3 (sometimes written as E883). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is E88.3 (Other and unspecified metabolic disorders) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report tumor lysis syndrome on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does E88.3 group to?
When tumor lysis syndrome is the principal diagnosis on an inpatient stay, it groups to MS-DRG 673, 674, 675, 682, 683, 684, 791, 793, with relative weights from 0.6003 to 4.2016 depending on complications. Higher weights mean higher Medicare reimbursement.
Is E88.3 a CC or MCC?
CMS lists E88.3 as an MCC (major complication or comorbidity) for FY 2026. Reported as a secondary diagnosis, it places the inpatient stay in the highest-weighted DRG of its severity family. It does not count when the principal diagnosis is one of the 78 closely related codes in its exclusion list.
What is the ICD-9 equivalent of E88.3?
Under the General Equivalence Mappings, tumor lysis syndrome converts to ICD-9-CM 277.88 (tumor lysis syndrome). The mapping is a direct match.
